HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bleomycin, cisplatinum and ifosfamide infusion chemotherapy in advanced/recurrent cancer of cervix.

Abstract
Twenty one patients age ranging from 26-70 years, with biopsy proven recurrent/advanced carcinoma of the cervix were treated with bleomycin, cisplatinum and ifosfamide infusion therapy. 88% patients reported subjective improvement. The objective response rate was 66.6% (Complete 38% and partial 28.5%). Side effects were mainly nausea, vomiting, and alopecia. Treatment related fever was common. Hematuria and reversible encephalopathy with ifosfamide were seen in three and two patients respectively. These results indicate that BIP infusion chemotherapy is an active and safe combination for treatment of advanced/recurrent cervical cancer.
AuthorsR M Singhal, R Jindel, A K Gupta
JournalIndian journal of cancer (Indian J Cancer) Vol. 30 Issue 4 Pg. 158-63 (Dec 1993) ISSN: 0019-509X [Print] India
PMID7515843 (Publication Type: Journal Article)
Chemical References
  • Bleomycin
  • Cisplatin
  • Ifosfamide
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Bleomycin (administration & dosage)
  • Carcinoma, Squamous Cell (drug therapy, mortality)
  • Cisplatin (administration & dosage)
  • Female
  • Humans
  • Ifosfamide (administration & dosage)
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy, mortality)
  • Survival Rate
  • Treatment Outcome
  • Uterine Cervical Neoplasms (drug therapy, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: